Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Multiple novel prostate cancer susceptibility signals identified by fine-mapping of known risk loci among Europeans.

Amin Al Olama A, Dadaev T, Hazelett DJ, Li Q, Leongamornlert D, Saunders EJ, Stephens S, Cieza-Borrella C, Whitmore I, Benlloch Garcia S, Giles GG, Southey MC, Fitzgerald L, Gronberg H, Wiklund F, Aly M, Henderson BE, Schumacher F, Haiman CA, Schleutker J, Wahlfors T, Tammela TL, Nordestgaard BG, Key TJ, Travis RC, Neal DE, Donovan JL, Hamdy FC, Pharoah P, Pashayan N, Khaw KT, Stanford JL, Thibodeau SN, Mcdonnell SK, Schaid DJ, Maier C, Vogel W, Luedeke M, Herkommer K, Kibel AS, Cybulski C, Wokołorczyk D, Kluzniak W, Cannon-Albright L, Brenner H, Butterbach K, Arndt V, Park JY, Sellers T, Lin HY, Slavov C, Kaneva R, Mitev V, Batra J, Clements JA, Spurdle A, Teixeira MR, Paulo P, Maia S, Pandha H, Michael A, Kierzek A, Govindasami K, Guy M, Lophatonanon A, Muir K, Viñuela A, Brown AA; PRACTICAL Consortium; COGS-CRUK GWAS-ELLIPSE (Part of GAME-ON) Initiative; Australian Prostate Cancer BioResource; UK Genetic Prostate Cancer Study Collaborators; UK ProtecT Study Collaborators, Freedman M, Conti DV, Easton D, Coetzee GA, Eeles RA, Kote-Jarai Z.

Hum Mol Genet. 2015 Oct 1;24(19):5589-602. doi: 10.1093/hmg/ddv203. Epub 2015 May 29.

2.

Methylation analysis of 79 patients with growth restriction reveals novel patterns of methylation change at imprinted loci.

Turner CL, Mackay DM, Callaway JL, Docherty LE, Poole RL, Bullman H, Lever M, Castle BM, Kivuva EC, Turnpenny PD, Mehta SG, Mansour S, Wakeling EL, Mathew V, Madden J, Davies JH, Temple IK.

Eur J Hum Genet. 2010 Jun;18(6):648-55. doi: 10.1038/ejhg.2009.246. Epub 2010 Jan 27.

3.

Identification of seven new prostate cancer susceptibility loci through a genome-wide association study.

Eeles RA, Kote-Jarai Z, Al Olama AA, Giles GG, Guy M, Severi G, Muir K, Hopper JL, Henderson BE, Haiman CA, Schleutker J, Hamdy FC, Neal DE, Donovan JL, Stanford JL, Ostrander EA, Ingles SA, John EM, Thibodeau SN, Schaid D, Park JY, Spurdle A, Clements J, Dickinson JL, Maier C, Vogel W, Dörk T, Rebbeck TR, Cooney KA, Cannon-Albright L, Chappuis PO, Hutter P, Zeegers M, Kaneva R, Zhang HW, Lu YJ, Foulkes WD, English DR, Leongamornlert DA, Tymrakiewicz M, Morrison J, Ardern-Jones AT, Hall AL, O'Brien LT, Wilkinson RA, Saunders EJ, Page EC, Sawyer EJ, Edwards SM, Dearnaley DP, Horwich A, Huddart RA, Khoo VS, Parker CC, Van As N, Woodhouse CJ, Thompson A, Christmas T, Ogden C, Cooper CS, Southey MC, Lophatananon A, Liu JF, Kolonel LN, Le Marchand L, Wahlfors T, Tammela TL, Auvinen A, Lewis SJ, Cox A, FitzGerald LM, Koopmeiners JS, Karyadi DM, Kwon EM, Stern MC, Corral R, Joshi AD, Shahabi A, McDonnell SK, Sellers TA, Pow-Sang J, Chambers S, Aitken J, Gardiner RA, Batra J, Kedda MA, Lose F, Polanowski A, Patterson B, Serth J, Meyer A, Luedeke M, Stefflova K, Ray AM, Lange EM, Farnham J, Khan H, Slavov C, Mitkova A, Cao G; UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology; UK ProtecT Study Collaborators; PRACTICAL Consortium, Easton DF.

Nat Genet. 2009 Oct;41(10):1116-21. doi: 10.1038/ng.450. Epub 2009 Sep 20.

4.

Multiple loci on 8q24 associated with prostate cancer susceptibility.

Al Olama AA, Kote-Jarai Z, Giles GG, Guy M, Morrison J, Severi G, Leongamornlert DA, Tymrakiewicz M, Jhavar S, Saunders E, Hopper JL, Southey MC, Muir KR, English DR, Dearnaley DP, Ardern-Jones AT, Hall AL, O'Brien LT, Wilkinson RA, Sawyer E, Lophatananon A; UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology; UK Prostate testing for cancer and Treatment study (ProtecT Study) Collaborators, Horwich A, Huddart RA, Khoo VS, Parker CC, Woodhouse CJ, Thompson A, Christmas T, Ogden C, Cooper C, Donovan JL, Hamdy FC, Neal DE, Eeles RA, Easton DF.

Nat Genet. 2009 Oct;41(10):1058-60. doi: 10.1038/ng.452. Epub 2009 Sep 20.

PMID:
19767752
5.

Mid-trimester hyperechogenic bowel in a fetus of Japanese origin: caution in interpreting reported CFTR mutation (L548Q).

Turner CL, Skinner AC, Castle BM, Wellesley DG.

Prenat Diagn. 2006 Sep;26(9):875-6. No abstract available.

PMID:
16941515
6.

Health reforms.

Castle BM.

N Z Med J. 1992 Dec 9;105(947):502-3. No abstract available.

PMID:
1461615
7.

Serial fetal blood sampling for the management of pregnancies complicated by severe rhesus (D) isoimmunization.

MacKenzie IZ, Bowell PJ, Castle BM, Selinger M, Ferguson JF.

Br J Obstet Gynaecol. 1988 Aug;95(8):753-8.

PMID:
3139022
8.

Prostaglandin release from preparations used vaginally for the induction of labour.

MacKenzie IZ, Castle BM, Mountford L, Ferguson J, Brennecke S, Embrey MP.

Prostaglandins. 1987 Dec;34(6):939-46.

PMID:
3482470
9.

In-utero intravascular transfusion of the fetus for the management of severe Rhesus isoimmunization--a reappraisal.

Mackenzie IZ, Bowell PJ, Ferguson J, Castle BM, Entwistle CC.

Br J Obstet Gynaecol. 1987 Nov;94(11):1068-73.

PMID:
3122818
10.

Maternal plasma prostaglandin E2 metabolite levels during human pregnancy and parturition.

Brennecke SP, Castle BM, Demers LM, Turnbull AC.

Br J Obstet Gynaecol. 1985 Apr;92(4):345-9.

PMID:
3857076
11.

The presence or absence of fetal breathing movements predicts the outcome of preterm labour.

Castle BM, Turnbull AC.

Lancet. 1983 Aug 27;2(8348):471-3.

PMID:
6136642

Supplemental Content

Loading ...
Support Center